Runx1 is a key regulator of articular cartilage homeostasis by orchestrating YAP, TGFβ, and Wnt signaling in articular cartilage formation and osteoarthritis

Abstract

Runt-related transcription factor 1 (Runx1) plays a key role in cartilage formation, but its function in articular cartilage formation is unclear. We generated non-inducible and inducible Runx1-deficient mice (Runx1 ^f/f Col2α1-Cre and Runx1 ^f/f Col2α1-CreER mice) and found that chondrocyte-specific Runx1-deficient mice developed a spontaneous osteoarthritis (OA)-like phenotype and showed exacerbated articular cartilage destruction under OA, characterized by articular cartilage degradation and cartilage ossification, with decreased Col2α1 expression and increased Mmp13 and Adamts5 expression. RNA-sequencing analysis of hip articular cartilage from the Runx1 ^f/f Col2α1-Cre mice compared to that from wild-type mice and subsequent validation analyses demonstrated that Runx1 is a central regulator in multiple signaling pathways, converging signals of the Hippo/Yap, TGFβ/Smad, and Wnt/β-catenin pathways into a complex network to regulate the expression of downstream genes, thereby controlling a series of osteoarthritic pathological processes. RNA-sequencing analysis of mutant knee joints showed that Runx1’s role in signaling pathways in articular cartilage is different from that in whole knee joints, indicating that Runx1 regulation is tissue-specific. Histopathologic analysis confirmed that Runx1 deficiency decreased the levels of YAP and p-Smad2/3 and increased the levels of active β-catenin. Overexpression of Runx1 dramatically increased YAP expression in chondrocytes. Adeno-associated virus-mediated Runx1 overexpression in the knee joints of osteoarthritic mice showed the protective effect of Runx1 on articular cartilage damaged in OA. Our results notably showed that Runx1 is a central regulator of articular cartilage homeostasis by orchestrating the YAP, TGFβ, and Wnt signaling pathways in the formation of articular cartilage and OA, and targeting Runx1 and its downstream genes may facilitate the design of novel therapeutic approaches for OA.

References

[1] Sharma L. Osteoarthritis year in review 2015: clinical. Osteoarthr. Cartil., 2016, 24: 36-48

[2] Hunter DJ. Pharmacologic therapy for osteoarthritis–the era of disease modification. Nat. Rev. Rheumatol., 2011, 7: 13-22

[3] Wang Y et al. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J. Bone Miner. Res., 2005, 20: 1624-1636

[4] Kimura A et al. Runx1 and Runx2 cooperate during sternal morphogenesis. Development, 2010, 137: 1159-1167

[5] Soung do Y et al. Runx1 dose-dependently regulates endochondral ossification during skeletal development and fracture healing. J. Bone Miner. Res., 2012, 27: 1585-1597

[6] Liakhovitskaia A et al. The essential requirement for Runx1 in the development of the sternum. Dev. Biol., 2010, 340: 539-546

[7] Lian JB et al. Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. J. Cell Physiol., 2003, 196: 301-311

[8] Tang J et al. Runt-related transcription factor 1 is required for murine osteoblast differentiation and bone formation. J. Biol. Chem., 2020, 295: 11669-11681

[9] Tang C-Y et al. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways. PLoS Genet., 2021, 17: e1009233-e1009233

[10] Tang CY et al. Runx1 up-regulates chondrocyte to osteoblast lineage commitment and promotes bone formation by enhancing both chondrogenesis and osteogenesis. Biochem. J., 2020, 477: 2421-2438

[11] Yano F et al. Runx1 contributes to articular cartilage maintenance by enhancement of cartilage matrix production and suppression of hypertrophic differentiation. Sci. Rep., 2019, 9

[12] Baird DA et al. Identification of novel loci associated with hip shape: a meta-analysis of genomewide association studies. J. Bone Min. Res, 2019, 34: 241-251

[13] Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr. Cartil., 2007, 15: 1061-1069

[14] Janssen JN et al. The influence of TGF-β3, EGF, and BGN on SOX9 and RUNX2 expression in human chondrogenic progenitor cells. J. Histochem. Cytochem., 2019, 67: 117-127

[15] Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-β: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol, 2017, 9: a022236

[16] Chandhoke AS et al. The ubiquitin ligase Smurf2 suppresses TGFβ-induced epithelial–mesenchymal transition in a sumoylation-regulated manner. Cell Death Differ., 2016, 23: 876-888

[17] Nie X, Liu H, Liu L, Wang YD, Chen WD. Emerging roles of Wnt ligands in human colorectal cancer. Front. Oncol, 2020, 10: 1341

[18] He C et al. YAP1-LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis. EMBO Rep, 2019, 20: e44948

[19] Zhou C et al. Runx1 protects against the pathological progression of osteoarthritis. Bone Res., 2021, 9: 50

[20] Davis JR, Tapon N. Hippo signalling during development. Development, 2019, 146: dev167106

[21] Matsumoto S et al. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling. Nat. Commun., 2019, 10

[22] Piersma B, Bank RA, Boersema M. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front. Med. (Lausanne), 2015, 2: 59

[23] Chuang LSH, Ito Y. The multiple interactions of RUNX with the Hippo-YAP pathway. Cells, 2021, 10: 2925

[24] Lundin V et al. YAP regulates hematopoietic stem cell formation in response to the biomechanical forces of blood flow. Dev. Cell, 2020, 52: 446-460.e445

[25] Meng G, Wei J, Wang Y, Qu D, Zhang J. miR-21 regulates immunosuppression mediated by myeloid-derived suppressor cells by impairing RUNX1-YAP interaction in lung cancer. Cancer Cell Int., 2020, 20

[26] Hoshi H et al. Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice. Cell Tissue Res., 2017, 368: 379-387

[27] Zhai G, Dore J, Rahman P. TGF-beta signal transduction pathways and osteoarthritis. Rheumatol. Int, 2015, 35: 1283-1292

[28] Ji C et al. RUNX1 plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal stem cells line C3H10T1/2, murine multi-lineage cells lines C2C12 and MEFs. Int. J. Mol. Sci., 2017, 18: 1348

[29] Wu M, Chen G, Li YP. TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res., 2016, 4: 16009

[30] Yamashiro T et al. Possible roles of Runx1 and Sox9 in incipient intramembranous ossification. J. Bone Miner. Res, 2004, 19: 1671-1677

[31] Luo Y et al. Runx1 regulates osteogenic differentiation of BMSCs by inhibiting adipogenesis through Wnt/β-catenin pathway. Arch. Oral. Biol., 2019, 97: 176-184

[32] Komori T. The functions of Runx family transcription factors and Cbfb in skeletal development. Oral. Sci. Int., 2015, 12: 1-4

[33] Kulkarni M et al. RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget, 2018, 9: 14175-14192

[34] Lin E, Kuo P-H, Liu Y-L, Yang AC, Tsai S-J. Transforming growth factor-β signaling pathway-associated genes SMAD2 and TGFBR2 are implicated in metabolic syndrome in a Taiwanese population. Sci. Rep., 2017, 7

[35] Xu L, Kitani A, Strober W. Molecular mechanisms regulating TGF-β-induced Foxp3 expression. Mucosal. Immunol., 2010, 3: 230-238

[36] Badlani N, Oshima Y, Healey R, Coutts R, Amiel D. Use of bone morphogenic protein-7 as a treatment for osteoarthritis. Clin. Orthop. Relat. Res., 2009, 467: 3221-3229

[37] Hayashi M, Muneta T, Ju YJ, Mochizuki T, Sekiya I. Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression. Arthritis Res. Ther., 2008, 10: R118

[38] Hayashi M et al. Intra-articular injections of bone morphogenetic protein-7 retard progression of existing cartilage degeneration. J. Orthop. Res., 2010, 28: 1502-1506

[39] Hunter DJ et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet. Disord., 2010, 11

[40] MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell, 2009, 17: 9-26

[41] Yu F-X, Zhao B, Guan K-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell, 2015, 163: 811-828

[42] Deng Y et al. Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation. Nat. Commun., 2018, 9

[43] Yui S et al. YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell, 2018, 22: 35-49.e37

[44] Pan JX et al. YAP promotes osteogenesis and suppresses adipogenic differentiation by regulating beta-catenin signaling. Bone Res., 2018, 6: 18

[45] Park HW et al. Alternative Wnt signaling activates YAP/TAZ. Cell, 2015, 162: 780-794

[46] Deng F et al. YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury. Cell Death Dis., 2018, 9: 153-153

[47] Gough NR. Understanding Wnt’s role in osteoarthritis. Sci. Signal., 2011, 4: ec134-ec134

[48] Chen M et al. Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis, 2007, 45: 44-50

[49] Nakamura E, Nguyen M-T, Mackem S. Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreERT to assay temporal activity windows along the proximodistal limb skeleton. Dev. Dyn., 2006, 235: 2603-2612

[50] Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthr. Cartil., 2010, 18: S17-S23

[51] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15

[52] Mirando, A. J., Dong, Y., Kim, J. & Hilton, M. J. in Skeletal Development and Repair: Methods and Protocols (ed Matthew J. Hilton) 267–277 (Humana Press, 2014).

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(AR070135)

U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)(AG056438)

China Scholarship Council (CSC)(201706290105)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)